Redmile Group, LLC — SEC Form 4 Insider Trading Activity

Summary

Updated Jul 16, 2026

Redmile Group, LLC has filed 3 SEC Form 4 filings across 1 company in the last 90 days — active on both sides. Lifetime open-market purchases: $1.44M. Lifetime open-market sales: $20.43M. Historical track record: 1/5 stars across 6 tracked purchases.

Profile

Redmile Group, LLC
RoleDirector, 10% Owner
Notability30/100

Track Record

InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.

InsiderAlpha rating★☆☆☆☆ (1/5)
Total purchases tracked6
Purchases with forward-return data6
30-day win rate1667%
90-day win rate0%
Avg 5-day return-720.18%
Avg 30-day return-1258.16%
Avg 90-day return-2265.57%
Best 30-day return+720.00%

Recent Transactions

DateTickerCompanyCodeSharesPriceValue
2026-04-23FATEFATE THERAPEUTICS INCJ — Other acquisition / disposition8.98M$0.00
2026-04-23FATEFATE THERAPEUTICS INCJ — Other acquisition / disposition8.98M$0.00
2026-04-03ADCTADC Therapeutics SAS — Open-market sale2.53M$3.28$8.29M
2026-04-03ADCTADC Therapeutics SAS — Open-market sale2.63M$3.28$8.64M
2026-04-03ADCTADC Therapeutics SAS — Open-market sale162.5K$3.80$617K
2026-04-03ADCTADC Therapeutics SAS — Open-market sale169.3K$3.80$643K
2026-04-03ADCTADC Therapeutics SAS — Open-market sale188.4K$3.75$707K
2026-04-03ADCTADC Therapeutics SAS — Open-market sale196.2K$3.75$736K
2025-08-14IGMSIGM Biosciences, Inc.D — Derivative transaction2.96M—
2025-06-30IGMSIGM Biosciences, Inc.A — Grant or award828$0.00
2024-12-26FATEFATE THERAPEUTICS INCP — Open-market purchase398.0K$1.68$669K
2024-12-26FATEFATE THERAPEUTICS INCS — Open-market sale341.6K$1.68$574K
2024-12-26FATEFATE THERAPEUTICS INCJ — Other acquisition / disposition1.08M$1.68$1.82M
2024-12-26FATEFATE THERAPEUTICS INCJ — Other acquisition / disposition1.08M$1.68$1.82M
2024-12-16FATEFATE THERAPEUTICS INCJ — Other acquisition / disposition30.1K—
2024-12-13ADCTADC Therapeutics SAP — Open-market purchase50.0K$3.81$190K
2024-12-13ADCTADC Therapeutics SAP — Open-market purchase50.0K$2.28$114K
2024-12-13ADCTADC Therapeutics SAP — Open-market purchase50.0K$3.81$190K
2024-12-13ADCTADC Therapeutics SAP — Open-market purchase50.0K$2.28$114K
2024-12-06ADCTADC Therapeutics SAJ — Other acquisition / disposition50.7K$2.07$105K

Companies — Last 90 Days

Frequently Asked Questions

Who is Redmile Group, LLC?

Redmile Group, LLC is a corporate insider — currently tracked as Director, 10% Owner of FATE THERAPEUTICS INC (FATE). InsiderAlpha tracks every SEC Form 4 filing in real time.

How many SEC Form 4 filings has Redmile Group, LLC submitted recently?

3 primary Form 4 filings in the last 90 days, covering 1 company.

Has Redmile Group, LLC been buying or selling stock?

Recorded transactions: 6 open-market purchases ($1.44M) and 9 open-market sales ($20.43M) across all tracked filings.

How accurate is Redmile Group, LLC's historical track record?

Across 6 tracked purchases, Redmile Group, LLC averaged -1258.2% avg 30-day return with a 1667% 30-day win rate. InsiderAlpha rates the track record at 1/5 stars.

Where can I see all of Redmile Group, LLC's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Learn More

Open the live Redmile Group, LLC profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.